Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Receivables (2022 - 2025)

Dianthus Therapeutics (DNTH) has 4 years of Receivables data on record, last reported at $5.0 million in Q3 2025.

  • For Q3 2025, Receivables rose 85.87% year-over-year to $5.0 million; the TTM value through Sep 2025 reached $5.0 million, up 85.87%, while the annual FY2024 figure was $200000.0, 59.51% down from the prior year.
  • Receivables reached $5.0 million in Q3 2025 per DNTH's latest filing, up from $39000.0 in the prior quarter.
  • Across five years, Receivables topped out at $5.6 million in Q4 2022 and bottomed at $39000.0 in Q2 2025.
  • Average Receivables over 4 years is $1.9 million, with a median of $917500.0 recorded in 2024.
  • Peak YoY movement for Receivables: surged 258.19% in 2024, then plummeted 97.62% in 2025.
  • A 4-year view of Receivables shows it stood at $5.6 million in 2022, then plummeted by 91.18% to $494000.0 in 2023, then skyrocketed by 63.36% to $807000.0 in 2024, then skyrocketed by 519.58% to $5.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $5.0 million in Q3 2025, $39000.0 in Q2 2025, and $1.0 million in Q1 2025.